Imcivree Explained: The Obesity Drug That Is Not a GLP-1

Most of the obesity medicine you read about in 2026 belongs to one family. Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo all work on the incretin system, and they are all aimed at the same enormous population.

Imcivree is a different kind of drug entirely, for a much smaller group of people, and understanding why takes about five minutes.

This article explains what Imcivree is, who its label covers, what its trials showed, how it compares to the GLP-1 drugs, and what it costs. It is not medical advice. Everything here describes what the FDA label, the manufacturer and the published trials say. Decisions about treatment belong to you and a healthcare provider.

What is Imcivree?

Imcivree is the brand name for setmelanotide, made by Rhythm Pharmaceuticals, a Boston company focused on rare neuroendocrine diseases. The FDA first approved it on November 25, 2020, and it is given as a once-daily injection under the skin from a 10 mg per mL multiple-dose vial [1].

It is a melanocortin-4 receptor agonist, usually shortened to MC4R agonist. That is the entire story of the drug in one phrase, and the rest of this article unpacks it.

What does the MC4R pathway actually do?

Your brain runs a system for keeping track of how much stored energy your body has. Fat tissue releases leptin. Leptin signals to neurons in the hypothalamus. Those neurons release signaling molecules derived from a protein called POMC. Those molecules bind to the melanocortin-4 receptor. And when MC4R is activated, the brain gets the message: energy stores are fine, you can stop being hungry, and metabolic rate can stay normal.

When any link in that chain is broken, the message never arrives. The result is not ordinary hunger. It is hyperphagia — persistent, intense hunger that eating does not relieve — combined with a metabolic rate that stays lower than it should be. Diet and exercise advice is close to useless against it, because the body is receiving a continuous signal that it is starving.

Setmelanotide acts directly on that receptor, downstream of the broken link. That is why it can help conditions where the pathway is impaired, and why it is not expected to do much for obesity where the pathway is working normally.

Who is Imcivree approved for?

The label covers three groups [1]:

Acquired hypothalamic obesity, in adults and children aged 4 and older. This is obesity that follows physical damage to the hypothalamus — most often from a brain tumor such as a craniopharyngioma, or from the surgery or radiation used to treat one, or from a traumatic brain injury [3].

Bardet-Biedl syndrome, in adults and children aged 2 and older. A rare inherited condition that affects cilia, the tiny structures on cells, including in the neurons that run the MC4R circuit.

POMC, PCSK1 or LEPR deficiency, in adults and children aged 2 and older, confirmed by genetic testing showing variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. These are ultra-rare single-gene conditions that break the pathway at different points.

And here is what the label explicitly does not cover, in its Limitations of Use section [1]:

• Obesity due to POMC, PCSK1 or LEPR variants classified as benign or likely benign
• Other types of obesity, including obesity associated with other genetic syndromes and general polygenic obesity

That second exclusion is the important one. Imcivree is not a stronger weight-loss drug that is hard to get. It is a treatment for a specific broken circuit, and it is not indicated for common obesity.

What was the big 2026 news?

On March 19, 2026 the FDA approved an expanded indication covering acquired hypothalamic obesity, making Imcivree the first and only approved therapy for that condition [2][4].

That matters because hypothalamic obesity has been a genuinely untreatable problem. A child survives a brain tumor, and then gains weight rapidly and uncontrollably for reasons that have nothing to do with willpower or family habits, and until 2026 there was nothing approved to offer. Rhythm estimates roughly 10,000 people in the US have the condition, an estimate the company draws from published literature, tumor registries and claims data [2].

What did the trials show?

TRANSCEND, in acquired hypothalamic obesity, was the pivotal trial for the 2026 approval. It randomized patients aged 4 and older to an up-to-8-week titration followed by 52 weeks of treatment; the FDA analyzed 142 patients, 94 on setmelanotide and 48 on placebo. BMI fell 15.84 percent in the setmelanotide group and rose 2.55 percent on placebo — a placebo-adjusted difference of 18.40 percentage points, with a 95 percent confidence interval of -21.94 to -14.85. Just over 60 percent of treated patients lost at least 10 percent of their BMI, against under 5 percent on placebo [1]. Rhythm’s own announcement of the same 142-patient dataset reports slightly different figures (-16.4 percent versus +2.4 percent, an 18.8 point difference, p below 0.0001); the numbers above are the ones in the FDA-approved label [2].

The trial also measured hunger, which for this condition matters as much as weight. In patients 12 and older, the weekly average “most hunger” score fell 2.5 points on setmelanotide versus 1.3 points on placebo (p = 0.0015) [2]. The most common side effects were skin hyperpigmentation, nausea, vomiting and headache, each in more than 20 percent of participants.

Bardet-Biedl syndrome. A 14-week randomized, placebo-controlled phase 3 trial with a 52-week open-label extension enrolled 38 patients aged 6 and older. The primary endpoint was the proportion of patients 12 and older reaching at least a 10 percent body weight reduction after 52 weeks of treatment: 32.3 percent did (95 percent CI 16.7 to 51.4, p = 0.0006). Skin hyperpigmentation occurred in 61 percent and injection site redness in 48 percent [6]. Results in the small Alström syndrome group in the same trial were inconclusive, and the FDA indication covers Bardet-Biedl syndrome only.

POMC and LEPR deficiency. Two single-arm, open-label phase 3 trials supported the original 2020 approval. Ten participants with POMC deficiency and 11 with LEPR deficiency were treated for about a year. Eight of 10 (80 percent) in the POMC trial and 5 of 11 (45 percent) in the LEPR trial lost at least 10 percent of body weight. “Most hunger” scores fell 27.1 percent in the POMC trial and 43.7 percent in the LEPR trial [7].

It is worth being honest about that last set: 21 patients total, no placebo group, open label. That design is normal and often unavoidable for ultra-rare disease, but it is far weaker evidence than the large randomized trials behind the GLP-1 obesity drugs.

How does Imcivree compare with Ozempic or Zepbound?

They are not competitors, and comparing their weight-loss percentages side by side is misleading.

	Imcivree (setmelanotide)	GLP-1 and GIP drugs
Mechanism	MC4R agonist, acts in the hypothalamus	Incretin receptor agonists
Who it is for	Rare genetic and acquired hypothalamic obesity	Type 2 diabetes and common obesity
Approved for general obesity	No — explicitly excluded	Yes, for the weight-management products
Dosing	Once-daily injection from a vial	Weekly injection, daily injection or daily tablet depending on product
Distinctive side effect	Skin darkening and new or changed moles	Gastrointestinal effects

A GLP-1 drug in a person with hypothalamic obesity is acting on a pathway that is not the broken one. That does not mean it does nothing — incretin drugs have been studied in these populations — but it is not addressing the specific defect. Setmelanotide is.

Conversely, setmelanotide in a person with ordinary polygenic obesity is acting on a circuit that is already working, which is the mechanistic reason the label excludes that use.

What are the warnings people should know about?

The label carries several that are unusual for an obesity medicine [1]:

• Disturbance in sexual arousal, including spontaneous penile erections. An erection lasting more than 4 hours requires emergency care.
• Depression and suicidal ideation.
• Serious hypersensitivity reactions, including anaphylaxis.
• Skin hyperpigmentation, darkening of existing moles and development of new moles. The label recommends a full body skin exam before starting treatment and periodically during it.
• Acute adrenal insufficiency in patients with acquired hypothalamic obesity — because hypothalamic damage often disrupts other pituitary hormones as well.
• Sodium imbalance in patients with acquired hypothalamic obesity who also have central diabetes insipidus.

The common adverse reactions listed at 20 percent or higher in at least one indication are skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression and spontaneous penile erection [1].

The skin effects are not a coincidence. The melanocortin system that regulates hunger overlaps with the one that regulates pigment, which is why activating it darkens skin.

How is it given?

The label describes a once-daily subcutaneous injection from a 10 mg per mL, 1 mL multiple-dose vial, with starting dosages that differ by indication and age [1]:

• Acquired hypothalamic obesity, age 4 and older: starting dosage 0.5 mg once daily for 2 weeks
• Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency, age 12 and older: starting dosage 2 mg once daily for 2 weeks
• Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency, ages 6 to under 12: 1 mg once daily for 2 weeks
• Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency, ages 2 to under 6: 0.5 mg once daily for 2 weeks

The recommended maintenance dosage for adults and children aged 6 and older is 3 mg once daily across all three indications. For children aged 4 to under 6 with acquired hypothalamic obesity, and for children aged 2 to under 6 in the other indications, the label sets the maintenance dose by body weight [1].

This section summarizes sections 2.2 to 2.5 of the FDA-approved prescribing information and the Instructions for Use that accompany the vial. It is background, not directions: the schedule that applies to a given patient is the one on their own prescription, set and adjusted by their prescriber.

What does it cost, and how do people get it?

Rhythm does not publish a public list price. Third-party US price reporting puts a single 10 mg per mL vial at about $3,706 [8]. At the 3 mg maintenance dosage, one vial covers roughly three days, which puts the estimated annual cost in the hundreds of thousands of dollars. Treat that annualized figure as an estimate — it is derived from a reported vial price and label dosing, not from a published list price, and it ignores insurance, rebates and manufacturer support.

Rhythm runs a support program called Rhythm InTune, which assigns Patient Education Managers to provide one-on-one disease education, resources and ongoing support. The company states plainly that these managers are Rhythm employees and do not provide medical care or advice [3].

For a rare-disease product at this price point, access typically runs through specialty pharmacy, prior authorization and genetic testing documentation. The testing requirement is not a formality: for the POMC, PCSK1 and LEPR indication, the label requires genetic confirmation with variants interpreted as pathogenic, likely pathogenic, or of uncertain significance, and excludes variants classified as benign or likely benign.

What is coming next?

Rhythm is developing bivamelagon, an investigational oral MC4R agonist, for hypothalamic obesity, along with a second investigational MC4R agonist called RM-718. A long-term phase 2 study of bivamelagon in hypothalamic obesity began enrolling by invitation on November 10, 2025 [9]. Neither is FDA approved.

If an oral MC4R agonist eventually reaches the market, it would remove the daily injection from a treatment that children as young as 4 currently receive every day. That is a meaningful quality-of-life difference for the families involved, though it is still years from being settled.

The short version

Imcivree is not a GLP-1 and is not a rival to Wegovy or Zepbound. It is a once-daily injection that acts on the MC4R hunger circuit in the hypothalamus, approved for three specific rare conditions in which that circuit is broken — and explicitly not approved for general obesity. Its 2026 expansion into acquired hypothalamic obesity gave that condition its first approved treatment. Its results in the right population are substantial, its side effect profile is distinctive, and its cost is very high.

If you or your child had a brain tumor, a hypothalamic injury, or a diagnosed genetic obesity syndrome and weight gain has been rapid and hunger constant, this is a drug worth asking a specialist about. If you are looking for a stronger version of Ozempic, this is not it.

Sources

1. IMCIVREE (setmelanotide) injection — US prescribing information, US Food and Drug Administration, 2026
2. Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity, Rhythm Pharmaceuticals, March 2026
3. IMCIVREE for Patients and Caregivers, Rhythm Pharmaceuticals
4. FDA Approves Setmelanotide for Adult and Pediatric Patients With Acquired Hypothalamic Obesity, The American Journal of Managed Care, 2026
5. TRANSCEND study record (NCT05774756), ClinicalTrials.gov
6. Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome, The Lancet Diabetes & Endocrinology, 2022
7. Efficacy and safety of setmelanotide in individuals with severe obesity due to LEPR or POMC deficiency, The Lancet Diabetes & Endocrinology, 2020
8. Imcivree prices, coupons and patient assistance programs, Drugs.com
9. Bivamelagon long-term study record (NCT07156578), ClinicalTrials.gov
10. Setmelanotide labels, DailyMed, National Library of Medicine